^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Kaitanni (cadonilimab)

    i
    Other names: AK104, AK-104, AK 104
    Company:
    Akesobio
    Drug class:
    PD1 inhibitor, CTLA4 inhibitor
    Related drugs:
    2d
    CLEAR-IT: Cadonilimab (AK104) Plus Lenvatinib in Previously Immunotherapy-Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=28, Active, not recruiting, RenJi Hospital | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Lenvima (lenvatinib) • Kaitanni (cadonilimab)
    3d
    Immunotherapy combined with chemotherapy as first-line treatment for HER2-negative advanced gastric or gastroesophageal junction cancer: systematic review and Bayesian network meta-analysis based on specific PD-L1 expression levels. (PubMed, BMC Cancer)
    In conclusion, these findings support immunotherapy-combination chemotherapy as a superior first-line strategy for HER2-negative advanced G/GEJC. Different optimal regimens can be selected based on PD-L1 expression levels, providing evidence-based guidance for clinical decision-making.
    Retrospective data • Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 negative
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Kaitanni (cadonilimab) • Cejemly (sugemalimab)
    5d
    A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT (clinicaltrials.gov)
    P3, N=378, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • albumin-bound paclitaxel • Kaitanni (cadonilimab)
    11d
    AK104-IIT-027: Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC (clinicaltrials.gov)
    P1/2, N=57, Active, not recruiting, Sichuan University | Recruiting --> Active, not recruiting | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Apr 2026 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    carboplatin • etoposide IV • Kaitanni (cadonilimab)
    11d
    LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study (clinicaltrials.gov)
    P2, N=74, Recruiting, Ruijin Hospital
    New P2 trial
    |
    CLDN18 (Claudin 18)
    |
    paclitaxel • Kaitanni (cadonilimab) • Teysuno (gimeracil/oteracil/tegafur)
    16d
    Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma (clinicaltrials.gov)
    P2, N=30, Recruiting, Shandong Cancer Hospital and Institute | Trial completion date: May 2026 --> Sep 2026 | Trial primary completion date: May 2025 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • paclitaxel • Kaitanni (cadonilimab)
    16d
    CCGLC-011: HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=44, Active, not recruiting, Tongji Hospital | Recruiting --> Active, not recruiting | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Dec 2025 --> Jun 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    5-fluorouracil • Lenvima (lenvatinib) • oxaliplatin • leucovorin calcium • Kaitanni (cadonilimab)
    17d
    A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104) (clinicaltrials.gov)
    P=N/A, N=610, Recruiting, Akeso
    New trial
    |
    Kaitanni (cadonilimab)
    17d
    Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006) (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, Sun Yat-sen University | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial primary completion date
    |
    cisplatin • paclitaxel • Kaitanni (cadonilimab)
    17d
    A Prospective, Single-Arm, Multicenter, Open-Label Phase II Clinical Study of Cadonilimab + Disitamab Vedotin ± Bevacizumab Combined with Radiotherapy in the Treatment of Locally Advanced or Stage IVB Cervical Cancer with Oligometastases (ChiCTR2600120786)
    P2, N=147, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    Avastin (bevacizumab) • Aidixi (disitamab vedotin) • Kaitanni (cadonilimab)
    17d
    Combination of regorafenib and cadonilimab treated with local advanced or metastatic hepatocellular carcinoma after first-line treatment failure:a single-arm open study (ChiCTR2600120728)
    P2, N=50, Recruiting, Department of Oncology, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology; Department of Oncology, T
    New P2 trial
    |
    Stivarga (regorafenib) • Kaitanni (cadonilimab)
    18d
    AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC) (clinicaltrials.gov)
    P2, N=73, Recruiting, Fudan University
    New P2 trial • pMMR
    |
    Kaitanni (cadonilimab)